what medicine can you not take with semaglutide Type 2 diabetes: New Ozempic pill now available in the U.S Popular weight loss drugs could

(WZTV) Tennessee lawmakers are moving forward with a rule change that would allow TennCare to cover FDA-approved weight-loss drugs for the treatment of obesity a shift supporters say could improve health outcomes for thousands of low-income residents, but one that critics warn could come with a high price tag

Yang A, Wu H, Lau ESH et al (2020) Trends in glucose-lowering drug use, glycemic control, and severe hypoglycemia in adults with diabetes in Hong Kong, 20022016

Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months

It works by increasing the concentration of neurotransmitters that naturally suppress pain signaling in the spinal cord